NanoVibronix, Inc.

Equities

NAOV

US63008J6038

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 04:30:00 2024-04-25 pm EDT			5-day change	1st Jan Change
0.75 ^USD	0.00%		0.00%	-34.78%

Apr. 08	NanoVibronix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	NanoVibronix, Inc. Enters into Letter of Intent with APOGEPHA Arzneimittel GmbH to Explore European Distribution Opportunity	CI

NANOVIBRONIX, INC. : Regulation FD Disclosure (form 8-K)

October 12, 2021 at 09:02 am EDT

Item 7.01. Regulation FD Disclosure.

On August 17, 2021, the Company issued a press release announcing new data from a study regarding its PainShield product. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.





Exhibit Number   Description

99.1               NanoVibronix, Inc, Press Release dated October 11, 2021
104              Cover Page Interactive Data File (embedded within the Inline XBRL
                 document)

Latest news about NanoVibronix, Inc.

NanoVibronix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 08	CI
NanoVibronix, Inc. Enters into Letter of Intent with APOGEPHA Arzneimittel GmbH to Explore European Distribution Opportunity	Dec. 04	CI
NanoVibronix, Inc. Signs Research Agreement for Clinical Study of UroShield with University of Michigan	Nov. 28	CI
NanoVibronix, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Investors Eye Fed Moves as US Futures Trend Lower in Friday's Premarket	23-10-20	MT
NanoVibronix, Inc. Gains Approval for Inclusion of UroShield Products in NHS Prescription Services' Drug Tariff	23-09-27	CI
NanoVibronix Files Registration Statement on Behalf of Selling Shareholders	23-09-13	MT
NanoVibronix to Raise $5 Million Through Securities Placement	23-08-30	MT
Top Midday Gainers	23-08-30	MT
NanoVibronix, Inc. announced that it expects to receive $5 million in funding	23-08-29	CI
NanoVibronix Says It's Working to Understand Implications of CMS Decision Related to PainShield Device	23-08-29	MT
NanoVibronix, Inc. Applies for Inclusion of Uroshield Products in Nhs Prescription Services' Drug Tariff	23-08-28	CI
NanoVibronix Extends Distribution Agreement With Ultra Pain Products for Ultrasound Therapy Devices; Shares Rise	23-08-23	MT
NanoVibronix Extends Distribution Agreement with Its Largest Distributor for PainShield and PainShield Plus	23-08-23	CI
NanoVibronix, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11	CI
NanoVibronix Announces Distribution Agreement with Mio-Guard	23-06-14	CI
NanoVibronix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
NanoVibronix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-17	CI
NanoVibronix, Inc. Receives Positive Final Results of Independent Lifecycle Testing of PainShield Prompted by Centers for Medicare and Medicaid Services	23-03-28	CI
NanoVibronix Files Provisional Patent Application in US for UroShield Ultra; Shares Jump	23-03-21	MT
NanoVibronix, Inc. Files Provisional U.S. Patent Application for UroShield Ultra	23-03-21	CI
Nanovibronix, Inc. Announces Positive Results from Independent Product Trial of UroShield for Patients with A Spinal Cord Injury	23-03-14	CI
NanoVibronix Regains Nasdaq Compliance for Listing	23-03-03	MT
Sector Update: Health Care Stocks Mostly Remain Mixed Late Wednesday	23-02-08	MT
Sector Update: Health Care	23-02-08	MT

Chart NanoVibronix, Inc.

Duration

Period

More charts

Company Profile

NanoVibronix, Inc. is a medical device company. The Company is focused on developing noninvasive biological response-activating devices utilizing its low-intensity surface acoustic wave (SAW) technology. Its primary products consist of UroShield and PainShield. UroShield is an ultrasound-based product that is designed to prevent bacterial colonization and biofilm in urinary catheters, increase antibiotic efficacy and decrease pain and discomfort associated with urinary catheter use, which markets in the United States under Food and Drug Administration (FDA) policy of enforcement discretion during the COVID-19 pandemic and is undergoing clinical testing. PainShield is a patch-based therapeutic ultrasound technology to treat pain, muscle spasm and joint contractures by delivering a localized ultrasound effect to treat pain and induce soft tissue healing in a targeted area. Its PainShield family of products includes PainShield MD and PainShield Plus.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-05-01 - Planet MicroCap Showcase

More about the company

Income Statement Evolution

More financial data

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
NANOVIBRONIX, INC.	-34.78%	2.09M
ABBOTT LABORATORIES	-2.92%	185B
MEDTRONIC PLC	-3.80%	105B
BECTON, DICKINSON AND COMPANY	-5.48%	66.59B
DEXCOM, INC.	+11.22%	54.66B
CENCORA, INC.	+16.74%	47.78B
HOYA CORPORATION	+4.06%	41.26B
WEST PHARMACEUTICAL SERVICES, INC.	+4.56%	26.95B
METTLER-TOLEDO INTERNATIONAL, INC.	+1.64%	26.37B
TERUMO CORPORATION	+12.96%	24.8B

Other Medical Equipment, Supplies & Distribution